CY1123408T1 - Φαρμακευτικες συνθεσεις και χρηση των αυτων - Google Patents

Φαρμακευτικες συνθεσεις και χρηση των αυτων

Info

Publication number
CY1123408T1
CY1123408T1 CY20201100535T CY201100535T CY1123408T1 CY 1123408 T1 CY1123408 T1 CY 1123408T1 CY 20201100535 T CY20201100535 T CY 20201100535T CY 201100535 T CY201100535 T CY 201100535T CY 1123408 T1 CY1123408 T1 CY 1123408T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
present disclosure
disclosure provides
provides pharmaceutical
micronized compound
Prior art date
Application number
CY20201100535T
Other languages
English (en)
Inventor
Zhongzhou Liu
Chongdong FU
Bin Shi
Original Assignee
Hutchison Medipharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Limited filed Critical Hutchison Medipharma Limited
Publication of CY1123408T1 publication Critical patent/CY1123408T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Η παρούσα αποκάλυψη παρέχει φαρμακευτικές συνθέσεις που περιλαμβάνουν την μικρονισμένη Ένωση Α και τη χρήση αυτής.
CY20201100535T 2015-05-25 2020-06-11 Φαρμακευτικες συνθεσεις και χρηση των αυτων CY1123408T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2015/079650 WO2016187767A1 (en) 2015-05-25 2015-05-25 Pharmaceutical compositions and use thereof
PCT/CN2016/083098 WO2016188399A1 (en) 2015-05-25 2016-05-24 Pharmaceutical compositions and use thereof

Publications (1)

Publication Number Publication Date
CY1123408T1 true CY1123408T1 (el) 2021-12-31

Family

ID=57392304

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100535T CY1123408T1 (el) 2015-05-25 2020-06-11 Φαρμακευτικες συνθεσεις και χρηση των αυτων

Country Status (26)

Country Link
US (1) US20180153890A1 (el)
EP (1) EP3302483B1 (el)
JP (1) JP6878309B2 (el)
KR (1) KR102573278B1 (el)
CN (1) CN107613984B (el)
AU (1) AU2016269304B2 (el)
BR (1) BR112017024126B8 (el)
CA (1) CA2985379C (el)
CY (1) CY1123408T1 (el)
DK (1) DK3302483T3 (el)
ES (1) ES2796575T3 (el)
HK (1) HK1245113A1 (el)
HR (1) HRP20200935T1 (el)
HU (1) HUE050697T2 (el)
LT (1) LT3302483T (el)
MX (1) MX2017014880A (el)
MY (1) MY188169A (el)
PH (1) PH12017502148A1 (el)
PL (1) PL3302483T3 (el)
PT (1) PT3302483T (el)
RS (1) RS60355B1 (el)
RU (1) RU2712187C2 (el)
SG (1) SG10202106375UA (el)
SI (1) SI3302483T1 (el)
TW (1) TWI714588B (el)
WO (2) WO2016187767A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7308145B2 (ja) 2016-11-18 2023-07-13 ハッチソン メディファーマ リミテッド 固形腫瘍を治療するための医薬組成物
CN111184698A (zh) * 2018-11-15 2020-05-22 和记黄埔医药（上海）有限公司 呋喹替尼制剂及其应用
US20220073642A1 (en) * 2020-09-07 2022-03-10 Hutchison Medipharma Limited Methods of using surufatinib in treating advanced pancreatic and extra-pancreatic neuroendocrine tumors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DE60309300T3 (de) * 2002-03-20 2011-02-24 Elan Pharma International Ltd. Nanopartikelzusammensetzungen von angiogeneseinhibitoren
MXPA06010543A (es) * 2004-03-15 2007-03-26 Ptc Therapeutics Inc Derivados de carbolina utiles en la inhibicion de la angiogenesis.
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JO2860B1 (en) * 2009-05-07 2015-03-15 ايلي ليلي اند كومباني Phenylendazolyl compounds
CN102070618B (zh) * 2009-11-23 2013-08-21 和记黄埔医药（上海）有限公司 一种化合物及其晶体
CN102775385A (zh) * 2011-05-10 2012-11-14 湖南有色凯铂生物药业有限公司 N-取代苯基-n’-取代杂环脲类化合物及其作为抗癌药物的应用

Also Published As

Publication number Publication date
WO2016187767A1 (en) 2016-12-01
LT3302483T (lt) 2020-06-25
RU2017139880A (ru) 2019-06-25
CN107613984B (zh) 2021-04-30
AU2016269304B2 (en) 2021-04-15
EP3302483A1 (en) 2018-04-11
SG10202106375UA (en) 2021-07-29
BR112017024126B8 (pt) 2023-05-09
BR112017024126A2 (pt) 2018-07-31
US20180153890A1 (en) 2018-06-07
SI3302483T1 (sl) 2020-07-31
TW201641108A (zh) 2016-12-01
CN107613984A (zh) 2018-01-19
CA2985379A1 (en) 2016-12-01
DK3302483T3 (da) 2020-06-15
JP6878309B2 (ja) 2021-05-26
CA2985379C (en) 2023-08-01
PH12017502148A1 (en) 2018-05-28
RU2712187C2 (ru) 2020-01-24
MY188169A (en) 2021-11-24
MX2017014880A (es) 2018-04-10
RU2017139880A3 (el) 2019-10-03
ES2796575T3 (es) 2020-11-27
KR20180006422A (ko) 2018-01-17
HK1245113A1 (zh) 2018-08-24
PT3302483T (pt) 2020-06-16
EP3302483B1 (en) 2020-04-15
BR112017024126B1 (pt) 2023-04-11
AU2016269304A1 (en) 2017-11-30
HRP20200935T1 (hr) 2020-09-18
JP2018515587A (ja) 2018-06-14
KR102573278B1 (ko) 2023-09-01
EP3302483A4 (en) 2019-02-27
RS60355B1 (sr) 2020-07-31
PL3302483T3 (pl) 2020-11-02
TWI714588B (zh) 2021-01-01
HUE050697T2 (hu) 2020-12-28
NZ737544A (en) 2021-06-25
WO2016188399A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
DK3529248T3 (da) Farmaceutiske sammensætninger
CY1123295T1 (el) Κρυσταλλικες μορφες της 5-χλωρο-ν4-[-2-(διμεθυλοφωσφορυλο) φαινυλο]-ν2-{2-μεθοξυ-4-[4-(4-μεθυλοπιπεραζιν-1-υλο)πιπεριδιν- 1-υλο]πυριμιδινο-2,4-διαμινης
DK3230281T3 (da) 1,3-thiazol-2-yl-substituerede benzamider
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
BR112016023628A2 (pt) composições farmacêuticas.
BR112017007158A2 (pt) composições para higiene oral compreendendo zinco, arginina e serina.
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
DK3634377T3 (da) Farmaceutisk formulering
CY1123408T1 (el) Φαρμακευτικες συνθεσεις και χρηση των αυτων
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
ES2841649T5 (es) Composición farmacéutica
DK3821905T3 (da) Insulin indeholdende farmaceutiske sammensætninger
CY1122287T1 (el) Ενωσεις χρησιμες για την αναστολη toy ror-γαμμα-τ
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
MA49837A (fr) Compositions pharmaceutiques
TR201901228T4 (tr) Vortioksetin piroglutamat.
BR112017002090A2 (pt) formulação de fator viii
MA47516A (fr) Composition pharmaceutique
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
DK3411008T3 (da) Sammensætninger omfattende aktive solbeskyttelsesmidler med polyhydroxyfulleren
DK3601277T3 (da) Farmaceutisk formulering
MA49625A (fr) Compositions pharmaceutiques
IT201700035964A1 (it) “divisorio per boiserie”